Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$69.80 USD

69.80
2,470,028

+0.87 (1.26%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $69.80 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Exact Sciences (EXAS) Q4 Earnings Top Estimates, Margin Falls

Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences (EXAS) Q4 top line.

Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of 20% and 6.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

DaVita (DVA) to Report Q4 Earnings: What's in the Offing?

High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) fourth-quarter top line.

Nalak Das headshot

5 Large-Cap Stocks Set to Beat on Q4 Earnings This Week

The following five large-cap stocks are set to beat Q4 earnings estimates this week. These are: TECK, LECO, NI, EXAS and GFL.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Why Earnings Season Could Be Great for Exact Sciences (EXAS)

Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exact Sciences (EXAS) Gains As Market Dips: What You Should Know

Exact Sciences (EXAS) closed at $65.52 in the latest trading session, marking a +0.17% move from the prior day.

Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AMN Healthcare (AMN) to Post Q4 Earnings: What's in the Cards?

AMN Healthcare's (AMN) fourth-quarter results are likely to reflect soft demand across the majority of its segments.

Insulet (PODD) to Report Q4 Earnings: What's in the Cards?

In Drug Delivery, Insulet (PODD) is expected to have faced higher manufacturing costs in Q4.

Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?

Ecolab's (ECL) fourth-quarter results are likely to reflect continued strength in its Global Industrial segment.

Exact Sciences (EXAS) Stock Moves -1.09%: What You Should Know

Exact Sciences (EXAS) closed the most recent trading day at $67.82, moving -1.09% from the previous trading session.

Exact Sciences (EXAS) Recently Broke Out Above the 20-Day Moving Average

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Urmimala Biswas headshot

3 MedTech Stocks Likely to Beat Estimates This Earnings Season

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EXAS, MDT and IART are poised ahead of their earnings releases.

Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?

Continued increase in Cologuard volume is likely to have benefited Exact Sciences (EXAS) Q4 performance.

Exact Sciences (EXAS) Stock Moves -0.46%: What You Should Know

Exact Sciences (EXAS) closed the most recent trading day at $67.14, moving -0.46% from the previous trading session.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Exact Sciences (EXAS) Dips More Than Broader Markets: What You Should Know

Exact Sciences (EXAS) closed the most recent trading day at $66.21, moving -1.88% from the previous trading session.

Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?

Here is how Exact Sciences (EXAS) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Here's How Much a $1000 Investment in Exact Sciences Made 10 Years Ago Would Be Worth Today

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Exact Sciences (EXAS) Stock Sinks As Market Gains: What You Should Know

Exact Sciences (EXAS) closed at $67.82 in the latest trading session, marking a -0.6% move from the prior day.

Exact Sciences (EXAS) Stock Moves -0.67%: What You Should Know

Exact Sciences (EXAS) closed at $67.92 in the latest trading session, marking a -0.67% move from the prior day.